Madelyn Yiseth Rojas Castro

Madelyn Yiseth Rojas Castro

Auto-generated profile, based on publicly available information

Madelyn Yiseth Rojas Castro

Affiliation EpiConcept, Paris, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2025 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
LALiliana Antunes
Liliana Antunes
MRMadelyn Rojas‐Castro
Madelyn Rojas‐Castro
MLMarcos Lozano
Marcos Lozano
IMIván Martínez‐Baz
Iván Martínez‐Baz
ILIsabel Leroux‐Roels
Isabel Leroux‐Roels
VTVebis Sari Ve Network Team
Vebis Sari Ve Network Team
We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID‐19 vaccines against PCR‐confirmed SARS‐CoV‐2 hospitalisation during the BA.2.86/JN.1 lineage‐predominant period using a multicentre test‐negative case–control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14–59 days and 34% at 60–119 days, with no effect thereafter. The XBB.1.5 COVID‐19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post‐vaccination.

25 November 2025 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
MRMadelyn Rojas‐Castro
Madelyn Rojas‐Castro
NVNuno Verdasca
Nuno Verdasca
SMSusana Monge
Susana Monge
LMLaurane De Mot
Laurane De Mot
CSCamino Trobajo Sanmartín
Camino Trobajo Sanmartín
ARAngela Mary Rose
Angela Mary Rose
We estimated COVID‐19 vaccine effectiveness (VE) against PCR‐confirmed SARS‐CoV‐2 hospitalization in patients ≥ 60 years with severe acute respiratory infection, using a multicenter, test‐negative, case–control study across seven sites in six European countries between September 2024 and May 2025. We included 352 cases (115 vaccinated; 33%) and 9980 controls (5024 vaccinated; 50%). VE was 42% (95% CI: 15; 61) 14–59 days post‐vaccination, 32% (95% CI: −1; 54) at 60–119 days, and 36% (95% CI: 2; 60) at 120–179 days, and no effect thereafter. Among adults aged 60–79 and ≥ 80 years, we observed moderate VE against COVID‐19 hospitalization for up to 2 and 4 months, respectively.

16 April 2023 in IJID Regions
Verified
Journal Article
Open access
JRJulia E. Rubin-Smith
Julia E. Rubin-Smith
MCMadelyn Yiseth Rojas Castro
Madelyn Yiseth Rojas Castro
IPIria Preza
Iria Preza
IHIris Hasibra
Iris Hasibra
JSJonilda Sulo
Jonilda Sulo
SBSILVIA BINO
SILVIA BINO
Healthcare workers have experienced high rates of morbidity and mortality from coronavirus disease 2019 (COVID-19). A prospective cohort study was conducted in three Albanian hospitals between 19 February and 14 December 2021. All participants underwent polymerase chain reaction (PCR) and serological testing at enrolment, regular serology throughout, and PCR testing when symptomatic. Vaccine effectiveness (VE) against COVID-19 and against all severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections (symptomatic or asymptomatic) was estimated. VE was estimated using a Cox regression model, with vaccination status as a time-varying variable. In total, 1504 HCWs were enrolled in this study; 70% had evidence of prior SARS-CoV-2 infection. VE was 65.1% [95% confidence interval (CI) 37.7–80.5] against COVID-19, 58.2% (95% CI 15.7–79.3) among participants without prior SARS-CoV-2 infection, and 73.6% (95% CI 24.3–90.8) among participants with prior SARS-CoV-2 infection. For BNT162b2 alone, VE was 69.5% (95% CI 44.5–83.2). During the period when the Delta variant was predominant, VE was 67.1% (95% CI 38.3–82.5). VE against SARS-CoV-2 infection for the full study period was 36.9% (95% CI 15.8–52.7). This study found moderate primary series VE against COVID-19 among healthcare workers in Albania. These results support the continued promotion of COVID-19 vaccination in Albania, and highlight the benefits of vaccination in populations with high levels of prior infection.

4 August 2021 in Injury Epidemiology
Verified
Journal Article
Open access
PDF file
MCMadelyn Yiseth Rojas Castro
Madelyn Yiseth Rojas Castro
LOLudivine Orriols
Ludivine Orriols
DSDunia Basha Sakr
Dunia Basha Sakr
BCBenjamin Contrand
Benjamin Contrand
MDMarion Dupuy
Marion Dupuy
ELEmmanuel Lagarde
Emmanuel Lagarde
Background: Home and leisure injuries (HLIs) are a major public health problem. Cohort studies among general population are needed for targeted preventive actions but remain scarce. We quantify and qualify the HLIs collected prospectively in the MAVIE (Mutualists against Home and Leisure Injuries) observatory, a web-based cohort among volunteers of the French general population. Methods: Participants reported HLIs from November 2014 to December 2019. We calculated crude and standardized incidence rates (SIRs) on the entire cohort, for each of the selected socio-demographic variables and each of the injury circumstances (place and activity), mechanisms, and injury severity levels. We also described other HLIs characteristics and consequences. Results: Out of the 29,931 household members enrolled in the cohort, 12,419 participants completed the questionnaires. Among them, 8640 participants provided follow-up data, leading to a follow-up of 6302 persons for 5.2 years and 2483 HLIs were reported. We obtained a SIR of 85.0 HLIs per 1000 persons-years. Most reported injuries did not require emergency department attendance or hospitalization (64%). SIRs were higher in children (< 15 years of age) (109.1 HLIs per 1000 persons-years; 95% CI, 78.2–140.1) and adults aged 70 years and older (123.7 HLIs per 1000 persons-years; 95% CI, 79.2–168.3). Struck or hit by fall was the most frequent injury mechanism (52%) and also among the most severe injuries (73% of Struck or hit by fall HLIs ending with hospitalization). Sport (without contact with nature), and leisure and play activities were the injury circumstances with higher SIRs, 15.2 HLIs per 1000 persons-years (95% CI, 14.6–15.8) and 11.2 HLIs per 1000 persons-years (95% CI, 10.7–11.6), respectively. Outdoor sport activity (in contact with nature) was the circumstance with the highest proportion of hospitalizations (18% of outdoor sports HLIs ending with hospitalization). Conclusion: The incidences, causes, and consequences of HLI differ by age group and are mainly related to the performance of certain activities. Although the participants in the MAVIE cohort were not representative of the French population. Our study identified potential sub-populations and specific types of HLIs that should be targeted by future studies concerning risk factors and prevention programs.

29 December 2025 in BMC Medicine
Verified
Journal Article
Open access
PDF file
MRMadelyn Rojas-Castro
Madelyn Rojas-Castro
RMRanya Mulchandani
Ranya Mulchandani
KBKim Brolin
Kim Brolin
ZMZvjezdana Lovrić Makarić
Zvjezdana Lovrić Makarić
AUAnneli Uusküla
Anneli Uusküla
CSCamelia Savulescu
Camelia Savulescu
Healthcare workers (HCWs) face high occupational exposure to SARS-CoV-2 and are a priority group for vaccination. Both natural infection and vaccination

6 September 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MKMark Katz
Mark Katz
MCMadelyn Yiseth Rojas Castro
Madelyn Yiseth Rojas Castro
GCGiorgi Chakhunashvili
Giorgi Chakhunashvili
NCNazibrola Chitadze
Nazibrola Chitadze
CWCaleb L Ward
Caleb L Ward
LSLia Sanodze
Lia Sanodze
Background: Healthcare workers (HCWs) have suffered considerable morbidity and mortality during the COVID-19 pandemic. Few data on COVID-19 vaccine effectiveness (VE) are available from middle-income countries in the WHO European Region. We evaluated primary series COVID-19 VE against laboratory-confirmed COVID-19 among HCWs in Georgia. Methods: HCWs in six hospitals in Georgia were invited to enroll in a prospective cohort study conducted during March 19–December 5, 2021. Participants completed weekly symptom questionnaires. Symptomatic HCWs were tested by RT-PCR and/or rapid antigen test (RAT), and participants were routinely tested for SARS-CoV-2 by RT-PCR or RAT, regardless of symptoms. Serology was collected at enrolment, and quarterly thereafter, and tested by electrochemiluminescence immunoassay for SARS-CoV-2 antibodies. We defined primary series vaccination as two doses of COVID-19 vaccine received ≥14 days before symptom onset. We estimated VE as (1-hazard ratio)*100 using a Cox proportional hazards model with vaccination status as a time-varying covariate. Estimates were adjusted by potential confounders that changed the VE estimate by more than 5%, according to the change-in-estimate approach. Results: Overall, 1561/3849 (41%) eligible HCWs enrolled and were included in the analysis. The median age was 40 (IQR: 30–53), 1318 (84%) were female, and 1003 (64%) had laboratory evidence of prior SARS-Cov-2 infection. At enrolment, 1300 (83%) were unvaccinated; By study end, 1082 (62%) had completed a primary vaccine series (69% BNT162b2 (Pfizer-BioNTech); 22% BBIBP-CorV (Sinopharm); 9% other). During the study period, 191(12%) participants had a new PCR- or RAT-confirmed symptomatic SARS-CoV-2 infection. VE against PCR- or RAT- confirmed symptomatic SARS-CoV-2 infection was 58% (95%CI: 41; 70) for all primary series vaccinations, 68% (95%CI: 51; 79) for BNT162b2, and 40% (95%CI: 1; 64) for BBIBP-CorV vaccines. Among previously infected HCWs, VE was 58% (95%CI: 11; 80). VE against medically attended COVID-19 was 52% (95%CI: 28; 68), and VE against hospitalization was 69% (95% CI: 36; 85). During the period of predominant Delta variant circulation (July-December 2021), VE against symptomatic COVID-19 was 52% (95%CI: 30; 66). Conclusions: Primary series vaccination with BNT162b2 and BBIBP-CorV was effective at preventing COVID-19 among HCWs, most of whom had previous infection, during a period of mainly Delta circulation. Our results support the utility of COVID-19 primary vaccine series, and the importance of increasing coverage, even among previously infected individuals.